These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 30755439)

  • 41. Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer.
    Kozyreva VK; Kiseleva AA; Ice RJ; Jones BC; Loskutov YV; Matalkah F; Smolkin MB; Marinak K; Livengood RH; Salkeni MA; Wen S; Hazard HW; Layne GP; Walsh CM; Cantrell PS; Kilby GW; Mahavadi S; Shah N; Pugacheva EN
    Mol Cancer Ther; 2016 Aug; 15(8):1809-22. PubMed ID: 27235164
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
    Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G
    Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237
    [TBL] [Abstract][Full Text] [Related]  

  • 43. WEE1 kinase inhibitor MK-1775 sensitizes oral tongue squamous cell carcinoma cells to radiation irrespective of TP53 status.
    Al-Jamaei AH; de Visscher JGAM; Subramanyam VR; Forouzanfar T; Sminia P; Doulabi BZ; Helder MN
    Oral Dis; 2023 Oct; 29(7):2640-2649. PubMed ID: 35672254
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.
    Ding YH; Zhou ZW; Ha CF; Zhang XY; Pan ST; He ZX; Edelman JL; Wang D; Yang YX; Zhang X; Duan W; Yang T; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():425-64. PubMed ID: 25624750
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.
    Kausar T; Schreiber JS; Karnak D; Parsels LA; Parsels JD; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
    Neoplasia; 2015 Oct; 17(10):757-66. PubMed ID: 26585231
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC.
    Takahashi Y; Sheridan P; Niida A; Sawada G; Uchi R; Mizuno H; Kurashige J; Sugimachi K; Sasaki S; Shimada Y; Hase K; Kusunoki M; Kudo S; Watanabe M; Yamada K; Sugihara K; Yamamoto H; Suzuki A; Doki Y; Miyano S; Mori M; Mimori K
    Ann Oncol; 2015 May; 26(5):935-942. PubMed ID: 25632068
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer.
    Gabrielli B; Bokhari F; Ranall MV; Oo ZY; Stevenson AJ; Wang W; Murrell M; Shaikh M; Fallaha S; Clarke D; Kelly M; Sedelies K; Christensen M; McKee S; Leggatt G; Leo P; Skalamera D; Soyer HP; Gonda TJ; McMillan NA
    Mol Cancer Ther; 2015 Dec; 14(12):2753-61. PubMed ID: 26516156
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the
    Gong X; Du J; Parsons SH; Merzoug FF; Webster Y; Iversen PW; Chio LC; Van Horn RD; Lin X; Blosser W; Han B; Jin S; Yao S; Bian H; Ficklin C; Fan L; Kapoor A; Antonysamy S; Mc Nulty AM; Froning K; Manglicmot D; Pustilnik A; Weichert K; Wasserman SR; Dowless M; Marugán C; Baquero C; Lallena MJ; Eastman SW; Hui YH; Dieter MZ; Doman T; Chu S; Qian HR; Ye XS; Barda DA; Plowman GD; Reinhard C; Campbell RM; Henry JR; Buchanan SG
    Cancer Discov; 2019 Feb; 9(2):248-263. PubMed ID: 30373917
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.
    Sehdev V; Peng D; Soutto M; Washington MK; Revetta F; Ecsedy J; Zaika A; Rau TT; Schneider-Stock R; Belkhiri A; El-Rifai W
    Mol Cancer Ther; 2012 Mar; 11(3):763-74. PubMed ID: 22302096
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
    Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined Aurora Kinase A and CHK1 Inhibition Enhances Radiosensitivity of Triple-Negative Breast Cancer Through Induction of Apoptosis and Mitotic Catastrophe Associated With Excessive DNA Damage.
    Li C; Liao J; Wang X; Chen FX; Guo X; Chen X
    Int J Radiat Oncol Biol Phys; 2023 Dec; 117(5):1241-1254. PubMed ID: 37393021
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
    Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
    Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
    [No Abstract]   [Full Text] [Related]  

  • 53. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
    Jin J; Fang H; Yang F; Ji W; Guan N; Sun Z; Shi Y; Zhou G; Guan X
    Neoplasia; 2018 May; 20(5):478-488. PubMed ID: 29605721
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer.
    Alcaraz-Sanabria A; Nieto-Jiménez C; Corrales-Sánchez V; Serrano-Oviedo L; Andrés-Pretel F; Montero JC; Burgos M; Llopis J; Galán-Moya EM; Pandiella A; Ocaña A
    Mol Cancer Ther; 2017 Nov; 16(11):2552-2562. PubMed ID: 28847989
    [TBL] [Abstract][Full Text] [Related]  

  • 55. c-Myc Is a Major Determinant for Antitumor Activity of Aurora A Kinase Inhibitor MLN8237 in Thyroid Cancer.
    Li Y; Li X; Pu J; Yang Q; Guan H; Ji M; Shi B; Chen M; Hou P
    Thyroid; 2018 Dec; 28(12):1642-1654. PubMed ID: 30226440
    [No Abstract]   [Full Text] [Related]  

  • 56. Pairing a prognostic target with potential therapeutic strategy for head and neck cancer.
    Lek SM; Li K; Tan QX; Shannon NB; Ng WH; Hendrikson J; Tan JWS; Lim HJ; Chen Y; Koh KKN; Skanthakumar T; Kwang XL; Chong FT; Leong HS; Tay G; Putri NE; Lim TKH; Hwang JSG; Ang MK; Tan DSW; Tan NC; Tan HK; Kon OL; Soo KC; Iyer NG; Ong CJ
    Oral Oncol; 2020 Dec; 111():105035. PubMed ID: 33091845
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer.
    Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
    Cancer Res Treat; 2020 Jan; 52(1):149-166. PubMed ID: 31291716
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV
    Xiao R; An Y; Ye W; Derakhshan A; Cheng H; Yang X; Allen C; Chen Z; Schmitt NC; Van Waes C
    Clin Cancer Res; 2019 Nov; 25(21):6463-6474. PubMed ID: 31266830
    [TBL] [Abstract][Full Text] [Related]  

  • 59. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.
    De Witt Hamer PC; Mir SE; Noske D; Van Noorden CJ; Würdinger T
    Clin Cancer Res; 2011 Jul; 17(13):4200-7. PubMed ID: 21562035
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rapalogs induce non-apoptotic, autophagy-dependent cell death in HPV-negative TP53 mutant head and neck squamous cell carcinoma.
    Alam MM; Marin Fermin J; Spiller PT; Burnett C; Rong X; Moore-Medlin T; Maxwell CO; Khandelwal AR; Nathan CO
    Mol Carcinog; 2022 Jan; 61(1):33-44. PubMed ID: 34598317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.